Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medco Settlement Sets “Gold Standard” For PBMs Ahead Of Medicare Rx

Executive Summary

Prosecutors expect that other pharmacy benefit management companies will adopt codes of conduct based on Medco's April 26 settlement with 20 state attorneys general and the U.S. Attorney in Philadelphia

You may also be interested in...



Caremark Settlement Reinforces PBM Disclosure, Rx Interchange Standards

Caremark's settlement of a federal investigation into AdvancePCS' business practices reinforces the rules for pharmacy benefit manager conduct that were first delineated in a Medco consent decree in April 2004

Caremark Settlement Reinforces PBM Disclosure, Rx Interchange Standards

Caremark's settlement of a federal investigation into AdvancePCS' business practices reinforces the rules for pharmacy benefit manager conduct that were first delineated in a Medco consent decree in April 2004

P&T Committees Will Be New Focus For Pharma Prosecutors

Pharmacy & therapeutic committees will be a focus of scrutiny for federal prosecutors once the Medicare Part D benefit takes effect in 2006, Boston U.S. Attorney's Office White Collar Crime Section Chief Michael Loucks said Jan. 31 during CBI's Pharmaceutical Marketing Compliance Congress in Washington, D.C

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel